Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 2, 2011, Pages 149-150

  Chihara, Shingo ^a   Shimizu, Riha ^a   Furukata, Satoshi ^a   Hoshino, Koichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; AORTA DISSECTION; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG ABSORPTION; DRUG DOSE REDUCTION; FEMALE; HEMATOCHEZIA; HEMODIALYSIS; HUMAN; INTESTINE INJURY; INTESTINE ISCHEMIA; KIDNEY DISEASE; LEUKOCYTOSIS;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MIDDLE AGED; SERUM; VANCOMYCIN;

EID: 78751560495     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.513066     Document Type: Article

References (12)

1. Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974;81:429-33
2. Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. Can Med Assoc J 2006;175:745-8
3. Delaney JA, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007;13:761-3
4. Smith A. Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro Surveill 2005;10:E050630.2
5. Bourgault AM, Lamothe F, Loo VG, Poirier L; CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in southern Quebec, Canada. Antimicrob Agents Chemother 2006; 50:3473-5
6. Zar FA, Bakkanagari SR, Moorthi K, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
7. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults 2010. Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
8. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium-difficile colitis with oral vancomycin - comparison of 2 dosage regimens Am J Med 1989;86:15-9
9. Thompson CM Jr, Long SS, Gilligan PH, Prebis JW. Absorption of oral vancomycin - possible associated toxicity. Int J Pediatr Nephrol 1983;4:1-4
10. Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis Ann Intern Med 1984;100:533-4
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections - efficacy and toxicity. Arch Intern Med 2006;166:2138-44
12. F reeman J, Stott J, Baines SD, Fawley WN, Wilcox MH Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005;56:988-9